Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Anti-drug antibodies (ADA)"'
Autor:
Steven James Swanson
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The FDA has released new draft guidance to standardize how immunogenicity of protein therapeutics is described in product labels. A key aspect to this new guidance is that companies should describe anti-drug antibodies that have clinical significance
Externí odkaz:
https://doaj.org/article/df11cad646254a54a7215ec88bc3123d
Publikováno v:
SLAS Technology, Vol 28, Iss 5, Pp 361-368 (2023)
The potential immunogenicity of therapeutic human and humanized monoclonal antibodies (mAb) is a significant concern, and so preclinical testing of therapeutic mAbs routinely includes assessment of anti-drug antibody (ADA) induction. Here, we report
Externí odkaz:
https://doaj.org/article/52507ca073f64c848e02f76e94ea1a2e
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Therapeutic antibodies can elicit unwanted immune responses in a subset of patients, which leads to the production of anti-drug antibodies (ADA). Some of these ADAs have been reported to effect the pharmacokinetics, efficacy and/or safety of the ther
Externí odkaz:
https://doaj.org/article/c1b9707ae39d4189929d30c1b14fcfcd
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/57b6ca729a84466c935bfa6e4d54bdcc
Autor:
Meredith E. Davis-Gardner, Jesse A. Weber, Jun Xie, Katja Pekrun, Eric A. Alexander, Kim L. Weisgrau, Jessica R. Furlott, Eva G. Rakasz, Mark A. Kay, Guangping Gao, Michael Farzan, Matthew R. Gardner
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionUse of adeno-associated virus (AAV) vectors is complicated by host immune responses that can limit transgene expression. Recent clinical trials using AAV vectors to deliver HIV broadly neutralizing antibodies (bNAbs) by intramuscular admi
Externí odkaz:
https://doaj.org/article/00463782da80486d88a3fbab8e5a811b
Autor:
Brianna C. Davey, Mary S. Pampusch, Emily K. Cartwright, Hadia M. Abdelaal, Eva G. Rakasz, Aaron Rendahl, Edward A. Berger, Pamela J. Skinner
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
T cells expressing a simian immunodeficiency (SIV)-specific chimeric antigen receptor (CAR) and the follicular homing molecule, CXCR5, were infused into antiretroviral therapy (ART) suppressed, SIV-infected rhesus macaques to assess their ability to
Externí odkaz:
https://doaj.org/article/dcd9f049ddbd4f4ea011577c4e6dd6e5
Autor:
Malte Lenders, Eva Brand
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Enzyme replacement therapy (ERT) with recombinant α-galactosidase A (AGAL) can lead to the formation of neutralizing anti-drug antibodies (ADA), which significantly limit treatment efficacy in patients with Fabry disease (FD). The effects of dose es
Externí odkaz:
https://doaj.org/article/d723306f2dc246b692e521a716b0d9f6
Autor:
Ali Bootwala, Hyun Hwan An, Meghan Whitney Franklin, Benjamin J. Manning, Lucy Y. Xu, Shruti Panchal, Joseph D. Garlick, Reshica Baral, Michael E. Hudson, Gevorg Grigoryan, Mark A. Murakami, Kristen Hopson, Daniel S. Leventhal
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The optimal use of many biotherapeutics is restricted by Anti-drug antibodies (ADAs) and hypersensitivity responses which can affect potency and ability to administer a treatment. Here we demonstrate that Re-surfacing can be utilized as a generalizab
Externí odkaz:
https://doaj.org/article/4a3b4c9302ed43f8bcb616f28001d45c
Autor:
Francesca Faustini, Nicky Dunn, Nastya Kharlamova, Malin Ryner, Annette Bruchfeld, Vivianne Malmström, Anna Fogdell-Hahn, Iva Gunnarsson
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-13 (2021)
Abstract Background Anti-drug antibodies (ADAs) can impact on the efficacy and safety of biologicals, today used to treat several chronic inflammatory conditions. Specific patient groups may be more prone to develop ADAs. Rituximab is routinely used
Externí odkaz:
https://doaj.org/article/b7257dfa012e4aaa8b14f9ea4767b718
Autor:
Yu. V. Medvedev, M. A. Kolganova, O. A. Sas, T. N. Komarov, E. N. Fisher, I. E. Shohin, Yu. I. Ammour
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 9, Iss 2, Pp 140-144 (2020)
Introduction. Neutropenia, which is an abnormally low concentration of neutrophils in the blood, is one of the common side effects in patients receiving radio- or chemotherapy. Neutropenia usually leads to higher risks of severe bacterial and fungal
Externí odkaz:
https://doaj.org/article/b0e3df8c29cb4260ba757cb13bbddecf